AU2002319583B2 - (Pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid X receptor modulators - Google Patents

(Pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid X receptor modulators Download PDF

Info

Publication number
AU2002319583B2
AU2002319583B2 AU2002319583A AU2002319583A AU2002319583B2 AU 2002319583 B2 AU2002319583 B2 AU 2002319583B2 AU 2002319583 A AU2002319583 A AU 2002319583A AU 2002319583 A AU2002319583 A AU 2002319583A AU 2002319583 B2 AU2002319583 B2 AU 2002319583B2
Authority
AU
Australia
Prior art keywords
optionally substituted
alkyl
independently
diisopropyl
octa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002319583A
Other languages
English (en)
Other versions
AU2002319583A1 (en
Inventor
Marcus F. Boehm
Kevin M. Gardinier
Timothy Alan Grese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Eli Lilly and Co
Original Assignee
Ligand Pharmaceuticals Inc
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc, Eli Lilly and Co filed Critical Ligand Pharmaceuticals Inc
Publication of AU2002319583A1 publication Critical patent/AU2002319583A1/en
Application granted granted Critical
Publication of AU2002319583B2 publication Critical patent/AU2002319583B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002319583A 2001-07-20 2002-07-18 (Pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid X receptor modulators Ceased AU2002319583B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30695101P 2001-07-20 2001-07-20
US60/306,951 2001-07-20
PCT/US2002/023017 WO2003007950A1 (en) 2001-07-20 2002-07-18 (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators

Publications (2)

Publication Number Publication Date
AU2002319583A1 AU2002319583A1 (en) 2003-05-22
AU2002319583B2 true AU2002319583B2 (en) 2005-08-25

Family

ID=23187597

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002319583A Ceased AU2002319583B2 (en) 2001-07-20 2002-07-18 (Pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid X receptor modulators

Country Status (7)

Country Link
US (1) US20040248913A1 (https=)
EP (1) EP1414450A1 (https=)
JP (1) JP2005514327A (https=)
AU (1) AU2002319583B2 (https=)
CA (1) CA2452541A1 (https=)
MX (1) MXPA04000613A (https=)
WO (1) WO2003007950A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368296A1 (en) * 2001-03-14 2003-12-10 Eli Lilly And Company Fluorinated trienes and their use as rxr modulators
WO2011103536A1 (en) * 2010-02-19 2011-08-25 Arizona Board Of Regents Multifunctional radical quenchers and their use
US10472340B2 (en) 2015-02-17 2019-11-12 Arizona Board Of Regents On Behalf Of Arizona State University Substituted phenothiazines as mitochondrial agents
AU2016220153B2 (en) 2015-02-17 2020-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US11390605B2 (en) 2016-08-25 2022-07-19 Arizona Board Of Regents On Behalf Of Arizona State University Substituted pyrimidine compounds as multifunctional radical quenchers and their uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012853A1 (en) * 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Dimer-selective rxr modulators and methods for their use
EP0790228A1 (en) * 1994-10-31 1997-08-20 Eisai Co., Ltd. Mono- or polyenic carboxylic acid derivative
WO2001019770A2 (en) * 1999-09-14 2001-03-22 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
EP1368296A1 (en) * 2001-03-14 2003-12-10 Eli Lilly And Company Fluorinated trienes and their use as rxr modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0790228A1 (en) * 1994-10-31 1997-08-20 Eisai Co., Ltd. Mono- or polyenic carboxylic acid derivative
WO1997012853A1 (en) * 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Dimer-selective rxr modulators and methods for their use
WO2001019770A2 (en) * 1999-09-14 2001-03-22 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile

Also Published As

Publication number Publication date
MXPA04000613A (es) 2004-05-05
US20040248913A1 (en) 2004-12-09
CA2452541A1 (en) 2003-01-30
WO2003007950A1 (en) 2003-01-30
JP2005514327A (ja) 2005-05-19
EP1414450A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
US6593493B1 (en) RXR modulators with improved pharmacologic profile
DE60204674T2 (de) Retinoid x rezeptormodulatoren
EP0873295B1 (en) Dimer-selective rxr modulators and methods for their use
AU2002258550A1 (en) Retinoid X receptor modulators
AU2002255732B2 (en) Fluorinated trienes and their use as RXR modulators
EP1583743A1 (de) Indol-phenylsulfonamid-derivate als ppar-delta aktivierende verbindungen
AU2002255732A1 (en) Fluorinated trienes and their use as RXR modulators
US5998654A (en) Retinoic acid receptor antagonist compounds and methods
AU2002319583B2 (en) (Pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid X receptor modulators
US6005007A (en) Retinoids, methods for their production and use
AU2002319583A1 (en) (Pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid X receptor modulators
WO2000026173A1 (en) Novel retinoids, methods for their production and use
AU767255B2 (en) Dimer-selective RXR modulators and methods for their use
EP1675825A2 (de) Indolin-derivate als ppar delta modulatoren
WO2000026172A1 (en) Trienoic retinoid compounds as retinoic acid receptor antagonists
CH602548A5 (en) Indane- and tetrahydronaphthalene-carboxylic acid derivs.
KR20060079254A (ko) 다이머-선택적 ｒｘｒ 변조물질 및 그의 사용방법

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired